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Abstract
The outcome of patients with follicular lymphoma (FL) experiencing disease progression 
within the first two years from first-line chemo-immunotherapy is poor and optimal 
subsequent management is uncertain. The combination of rituximab, dexamethasone, 
high-dose cytarabine, and cisplatin/oxaliplatin (R-DHAP/Ox) is active in germinal center-
derived diffuse large B-cell lymphoma and is commonly used in FL prior to autologous 
stem cell transplantation (ASCT) in some Italian institutions. We identified all patients 
with FL that underwent R-DHAP/Ox at 3 institutions and retrospectively collected 
relevant clinical data. A total of 62 patients were identified, 46 of whom had relapsed 
within the first two years from the start of frontline chemo-immunotherapy, and 34 of 
whom underwent ASCT. The overall survival (OS) of patients relapsing in the first 2 
years after chemo-immunotherapy was of 74.3% at 5 years (95% C.I. 61-87%), the 
median time to next treatment (TTNT) after R-DHAP/Ox was 30.9 months (95% C.I. 18-
74). Among patients that received ASCT the 5-year OS was 83.8% and the median 
TTNT was 38.5 months. Multivariate analysis of FLIPI at diagnosis, number of therapies 
prior to R-DHAP/Ox, response after first line and progression within 2 years from first 
line, did not demonstrate an association with OS for the considered variables. 
Prospective trials with R-DHAP/Ox +/- ASCT in patients with FL relapsing within 2 years 
of frontline therapy are warranted.
Introduction
Data from the LymphoCare study1 demonstrated that patients with indolent follicular 
lymphoma that progresses within two years from the start of first-line chemo-
immunotherapy with R-CHOP have a median overall survival (OS) of 5 years from the 
time of progression. These patients represent around 20% of all FL treated with first-line 
with chemo-immunotherapy, and for them optimal subsequent treatment remains 
uncertain.
Second-line chemo-immunotherapy followed by consolidation with autologous stem cell 
transplantation (ASCT) has demonstrated significant activity in patients with previously 
treated FL2-4. While selection of second-line therapy is frequently based on institutional 
standards, the combination of rituximab, dexamethasone, high-dose cytarabine, and 
cisplatin/oxaliplatin (R-DHAP/Ox)5 is an attractive option because it demonstrated 
superior outcomes to ifosfamide-based therapy in previously treated diffuse large B cell 
lymphoma with germinal center subtype6, which shares the same cell of origin as FL. 
We hypothesized that the R-DHAP/Ox would be active therapy in patients with FL 
relapsing within the first two years following frontline chemoimmunotherapy and 
performed a retrospective study to evaluate the hypothesis.
Methods
The study was performed in accordance with IRB-approved protocols at each site 
(Universita' di Torino, San Bortolo Hospital, Citta' della Salute e della Scienza di Torino). 
All subjects had provided informed consent for the use of the clinical data. Patients were 
considered eligible if they had FL, if they had received at least one line of prior chemo-
immunotherapy, and had received R-DHAP/Ox following disease progression. Subjects 
with histological transformation or grade 3B FL prior to receiving R-DHAP/Ox were 
excluded. Investigators recorded clinical data from electronic and paper medical 
records, including number and type of therapies before and after R-DHAP/Ox, response 
to R-DHAP/Ox and ASCT, main adverse events (infections requiring admission, 
inadequate stem cell collection, secondary malignancies, transformation to DLBCL), 
and survival outcomes. Response was estimated by investigators at each site based on 
standard International Working Group Criteria7.
Data of the patients were analyzed anonymously. OS was calculated from risk-defining 
events, as reported in the LymphoCare study1, that is survival from the time of 
progression of disease (POD) for patients progressing in the first 2 years from first-line 
chemo-immunotherapy and from 2 years after diagnosis for the other group. 
Time to next therapy (TTNT) was calculated from the end of one line of therapy to start 
of the subsequent one. Survival probability was estimated with the Kaplan-Meyer 
method and difference between groups was tested by log-rank test. Cox proportional 
hazard regression was used to calculate hazard ratio and test the statistical 
significance. Median follow-up time was estimated by reverse Kaplan-Meier method. All 
analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). 
The primary objective was to describe the OS of patients that had experienced 
progressive disease within two years after first-line chemo-immunotherapy undergoing 
R-DHAP/Ox +/- ASCT as salvage treatment. Secondary objectives were TTNT after R-




A total of 67 patients, 42 men and 25 women, were identified; 62 met the eligibility 
criteria. Five patients were excluded: 2 progressed to DLBCL before starting R-
DHAP/Ox, 1 had grade 3b FL, 1 had a previous high grade lymphoma, 1 underwent 
chemotherapy in first line without anti-CD20 immunotherapy. Characteristics of the 
population at diagnosis are summarized in table 1. 
First line therapy
First-line therapy was rituximab-cyclophosphamide-doxorubicin-vincristin-prednisone 
(R-CHOP) in 46 (74.2%), R-fludarabine-mitoxantrone in 5 (8%), rituximab-
cyclophosphamide-vincristine-prednisone (R-CVP) in 4 (6.4%), R-bendamustine in 2 
(3.2%), rituximab-fludarabine-mitoxantrone-dexamethasone (R-FND) in 2 (3.2%), and 1 
of each of R-chlorambucil, R-bendamustine-mitoxantrone and R-HDS (HD sequential of 
etoposide, cyclophosphamide, mitoxantrone, melphalan + ASCT). Rituximab 
maintenance after first-line was given to 13 patients (21%). Prior to R-DHAP/Ox, 45 
(72.6%) underwent only 1 line of therapy, 14 (22.4%) underwent 2 lines of therapy, and 
3 (5%) had 3 or more lines.
Response to first-line chemo-immunotherapy was achieved in 92% (58% complete 
response [CR]); 5 patients (8%) reached only a stable disease (SD). The median TTNT 
from first-line was 22.1 months (95% C.I. 13.5 – 24.7), 48 patients progressed within the 
first two years (median TTNT 14.3 months [95% C.I. 10.6 – 19.4]). The characteristics 
of these early progressors relative to the population from the LymphoCare study 
are provided in Table 2. Overall response to last therapy prior to R-DHAP/Ox was 
87.1% (CR 58%), 6.4% had a stable disease, and 4.8% were in progression of disease. 
For one patient (1.6%), assessment of response was not reported.
R-DHAP/Ox +/- ASCT
Response to R-DHAP/Ox and ASCT for the whole population and for the early 
progressors is reported in table 3. Of the patients with early POD after first line, 34 
(74%) underwent consolidation with ASCT, 12 patients did not. In 5 cases (42%) this 
was due to progression of disease, in 3 cases (25%) patients had stem cell collection 
problems, in 2 cases (16.5%) infectious complications during R-DHAP/Ox precluded 
further high dose treatment. The remaining 2 patients consolidated R-DHAP/Ox with 
radio-immunotherapy. 
Radio-immunotherapy with ibritumomab tiuxetan (zevalin) was used in 22 total patients 
(35.5%) pre- or post R-DHAP/Ox and ASCT, and 10 patients (16%) underwent 
rituximab maintenance after ASCT.
Toxicity
Febrile neutropenia was reported in 10 cases (16%), delay of chemotherapy in 5 cases 
(8%). In 3 cases, a dose reduction of the therapy by 80% from the beginning was 
reported, due to age or comorbidities. One patient needed a dose reduction for renal 
toxicity. Stem cell collection failure was noticed in 6/52 cases (11.5%). Four patients 
(6.4%) experienced transformation to DLBCL, and 4 secondary malignancies, including 
3 myeloid disorders (2 acute leukemia, 1 myelodysplastic syndrome), 1 bladder 
carcinoma were reported.
Survival 
At the time of the analysis, 41 patients were still alive (66%). The causes of death were 
progression of lymphoma in 11 subjects (52%), secondary myeloid disorders in 3 
patients (14%), and other toxicity in 4 patients (19%: 1 related to autologous and 1 to 
allogeneic transplant, 1 renal toxicity plus unspecified neurological syndrome, 1 to 
pneumonia). In 1 case (4.7%) the death was unrelated to lymphoma or toxicity, and in 2 
cases (9.5%) the cause of death was not reported.
After a median follow-up of 66 months, median OS, OS at 5 years and TTNT after R-
DHAP/OX +/- ASCT for the population resulted as reported in table 4.  (figure 1)
A multivariate analysis on OS with 4 covariates (FLIPI, progression within 2 years, 
number of therapies before R-DHAP/Ox, response after first line), showed that after R-
DHAP/Ox +/- ASCT, none of these variables had impact on survival.
Overall, 35 patients (56.4%) relapsed after R-DHAP/Ox +/- ASCT, and 34 (54.8%) 
required further treatment, this representing in most of the cases a third line. 
Subsequent therapies are being summarized in table 5.
Discussion
To our knowledge, this is the first study to evaluate R-DHAP/Ox and ASCT in patients 
with FL and early progression following first-line immunochemotherapy. Our data 
suggest that treatment of these high-risk patients with R-DHAP/Ox and ASCT is active 
and reasonable. 
Compared to the LymphoCare population, our series of Italian patients with early POD 
had similar characteristics with the sole exception being that the average age in our 
series was slightly less than the LymphoCare patients, perhaps because these patients 
were selected to receive intensive therapy (table 2). The OS in this series appears 
superior to the LymphoCare study (OS at 5 years 74.3% vs 50%), and this is particularly 
evident for the group undergoing ASCT (OS at 5 years 83.8%). In the LymphoCare 
study, of people experiencing early POD, only in 7.3% were treated with ASCT, making 
a direct comparison not possible1.
This advantage in overall survival could be attributed to effectiveness of this radical 
program, but some bias might be contributing to that. First of all, this is a selected 
population, fit enough to undergo an intensive treatment, and probably does not 
represent all the FL with early POD at our institutions. Also, in the LymphoCare study, 
patients undergoing observation before first-line chemoimmunotherapy were excluded 
from the analysis, while in our cohort 8.6% of the patients underwent watchful waiting. 
To avoid this bias, we calculated the 2-year POD starting from the date of the first cycle 
of first-line chemotherapy, and not from diagnosis.       
One other series has evaluated treatment with single agent PI3K inhibitor idelalisib in FL 
with early POD8 and found that ORR was 56.8% (CR 13.5%), median duration of 
response was 11.8 months, and OS at 5 years from relapse after first-line 
chemotherapy 79%. Our series demonstrated better response rates and duration of 
response, but similar OS. Patients undergoing ASCT in our cohort did better overall. As 
noted previously, comparing patient populations across studies is challenging. Patients 
in the idelalisib study were treated in the context of a prospective protocol and received 
a median of three prior lines of therapy while our cohort consists of retrospectively 
identified patients treated in a standard clinical setting, and patients mostly received 
only one prior line of therapy.
TTNT following R-DHAP/Ox in our series was nearly three times TTNT after first-line 
therapy. Although most patients required additional therapy within 3 years, most cases 
were well controlled with less aggressive treatment (for example localized radiotherapy), 
or with a milder chemotherapy, like BR. This might indicate that the disease has 
probably a less aggressive behavior than before, and R-DHAP/Ox + ASCT might have 
eliminated some dangerous sub-clones that were responsible for this.
Both short-term and late toxicities in this series were consistent with previously reported 
series. In particular, despite a significant burden of therapy including 
radioimmunotherapy in 35.5%, myelodysplasia and myeloid leukemia appear to be 
comparable to other series with less intensive treatments9-12. 
The multivariate analysis on the whole population, showed that early POD did not 
predict poor outcome. This could derive from two factors: Our early POD population has 
a better outcome than the LymphoCare early POD population while our later-
progressing patient population was very small and had a worse prognosis than the one 
of the LymphoCare study. Probably these patients were selected for intensive therapy 
due to some other high risk features not identified in our collected data. All the other 
variables, such as response to first line, number of therapy lines before R-DHAP/Ox and 
FLIPI score, failed to predict outcome. Again, the small number of patients and events 
might have biased results.
Although these data are encouraging, the ideal approach to early POD FL is still far 
from standardized. Our data confirm that patients with FL and early POD have a poor 
prognosis, but also suggest that R-DHAP/Ox +/- ASCT may be effective therapy in this 
challenging population. Prospective studies of R-DHAP/Ox +/- ASCT are warranted in 
high-risk FL.
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Age at diagnosis Median 52 y 24-75
























































FLIPI: Follicular Lymphoma International Prognostic Index; NA: not available; R: 
rituximab; CHOP: cyclophosphamide-doxorubicin-vincristin-prednisone; CVP: 
cyclophosphamide-vincristine-prednisone; FND: fludarabine-mitoxantrone-
dexamethasone; HDS: sequential high-dose of etoposide-cyclophosphamide-
mitoxantrone-melphalan + autologous stem cell transplantation.
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Italian patients
Early POD (n=46)
















  Female 38                     35 15                       34 19                       51
  Male 72                     65 31                       66 18                       49
Histologic Grade
  1 or 2
  3a
  Missing
63                     66
33                     34
14
36                       78
10                       22
0
33                       89
4                         11
0
FLIPI score
  Low, 0 to 1
  Intermediate, 2
  High, 3 to 5
  Missing
10                     12
29                     34
47                     54
24
7                         15
13                       30




21                    56.8
NA
Table 2: Characteristics of the Italian population compared to the cohort of the 
LymphoCare study that relapsed within 2 years from R-CHOP. 
POD: progression of disease; FLIPI: Follicular Lymphoma International Prognostic 
Index, NA: not available.










(range 0.2- 27,3 months)
Response to R-DHAP/Ox ORR: 87.2% (CR 56%)
SD: 6.4%
ORR: 86.9% (CR 54%)
SD: 6.6%
PD: 3.2%
NA: 3.2%  
PD: 4.4%
NA: 2.1%  
Consolidation with ASCT 44 patients: 71% 34 patients: 74%
Response to R-DHAP/Ox 
and ASCT
ORR: 91% (CR 81.8%)
SD: 2.3%
PD: 2.3%
NA: 4.4%  
ORR: 91.3% (CR 79.4%)
SD: 0
PD: 2.9%
NA: 5.8%  
POD: progression of disease; ORR: overall response rate; CR: complete response; SD: 
stable disease; PD: progression of disease; NA: not available. 





Early POD undergoing 
R-DHAP/Ox +/- ASCT
(n=46)





(95% C.I. 86.5 - .)
100.1 months
(95% C.I. 82.1 - .)
Not reached
(95% C.I. 83.0 - NR)
5y OS 79.6% +/- 5.3
(95% C.I. 69.2% – 
89.9%) 
74.3% +/- 6.7
(95% C.I. 61.2% - 
87.4%)
83.8% +/- 6.7
(95% C.I. 70.6% - 
96.9%)
TTNT 38.5 months
(95% C.I. 18.9 - .)
30.9 months
(95% C.I. 18.4 – 74.0)
38.5 months
(95% C.I. 19.0 - .)
OS: overall survival; TTNT: time to next treatment; POD: progression of disease; C.I.: 
confidence interval.
Table 5. Subsequent treatments.







alkylators (n=10), 29% 
anthracyclines (n=4), 11%, 
purine analogs (n=6), 17%





Localized radiotherapy alone (n=2), 6%
Pi3K inhibitors (n=2), 6%
Lenalidomide + localized radiotherapy (n=1), 3%
BCL-2 inhibitor (n=1), 3%
Overall subsequent non-chemotherapy
rituximab (n=26), 76.5%, 
lenalidomide (n=9), 26.5%, 
PI3K inhibitor (n=6), 17.6%, 
BCL2 inhibitor (n=3), 8.8%.
Missing (n=1), 3%
Figure 1
OS from risk-defining events (from relapse for early POD and from 2 years after 
diagnosis for patients relapsing later than 2 yars) of early vs late POD after first line, 
p=0.29 (A); TTNT after R-DHAP/Ox +/- ASCT for early POD vs late POD after first line, 
p=0.08 (B).  
